Effect of clindamycin on intracellular replication, protein synthesis, and infectivity of Toxoplasma gondii
Open Access
- 1 December 1993
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 37 (12) , 2571-2577
- https://doi.org/10.1128/aac.37.12.2571
Abstract
We studied the effects of clindamycin and a combination of clindamycin and pyrimethamine on the proliferation of Toxoplasma gondii in cultured mammalian cells and the effect of clindamycin on the parasite's RNA and protein syntheses. Infected macrophages were treated for 48 h with clindamycin or a combination of clindamycin and pyrimethamine, and the 50% inhibitory concentrations for parasite growth were 32.50 +/- 1.30 and 10.78 +/- 0.56 micrograms/ml, respectively. A modified susceptibility assay was also used to measure the effect of low concentrations of clindamycin on T. gondii. Macrophages and bovine turbinate cells were infected with low numbers of tachyzoites and were exposed to low concentrations of clindamycin for 5 days. In these systems, a concentration of 10 ng of clindamycin per ml inhibited 50% of the growth of the parasite in macrophages, while it completely prohibited the growth of the parasite in epithelial cells. When free tachyzoites were preexposed to clindamycin for 4 h, the reduction of parasite infectivity was proportional to the amount of drug; 100 ng of clindamycin per ml reduced the infectivity of T. gondii to 46.5% +/- 8.5% of that of the untreated control. A concentration of 40 micrograms of clindamycin per ml reduced protein synthesis by 56.2% +/- 6.0% but had no effect on RNA synthesis after a 4-h exposure of free tachyzoites of T. gondii to the drug. Our results show that long-term exposure to low concentrations of clindamycin reduces the level of replication of T. gondii, that clindamycin affects the protein synthesis of free parasites, and that clindamycin impairs the ability of tachyzoites to infect host cells.Keywords
This publication has 31 references indexed in Scilit:
- Treatment of acute toxoplasmosis with intravenous clindamycinEuropean Journal of Clinical Microbiology & Infectious Diseases, 1991
- Evaluation of the efficacy and safety of clindamycin plus pyrimethamine for induction and maintenance therapy of toxoplasmic encephalitis in AIDSEuropean Journal of Clinical Microbiology & Infectious Diseases, 1991
- A retrospective study of primary and maintenance therapy of toxoplasmic encephalitis with oral clindamycin and pyrimethamineEuropean Journal of Clinical Microbiology & Infectious Diseases, 1991
- Role of clindamycin in the treatment of acute toxoplasmosis of the central nervous systemEuropean Journal of Clinical Microbiology & Infectious Diseases, 1991
- Treatment of acute toxoplasmosis with oral clindamycinEuropean Journal of Clinical Microbiology & Infectious Diseases, 1991
- Current Recommendations and Future Prospects in the Treatment of ToxoplasmosisDrugs, 1989
- An Open Study of the Pyrimethamine-Clindamycin Combination in AIDS Patients with Brain ToxoplasmosisThe Journal of Infectious Diseases, 1989
- In Vitro Assessment of Antimicrobial Agents Against Toxoplasma gondiiThe Journal of Infectious Diseases, 1988
- Toxoplasma modifies macrophage phagosomes by secretion of a vesicular network rich in surface proteins.The Journal of cell biology, 1986
- Clindamycin Activity Against Chloroquine-Resistant Plasmodium falciparumThe Journal of Infectious Diseases, 1984